Literature DB >> 12874159

The HAART side of resource allocation.

Pedram Sendi1, Amiram Gafni.   

Abstract

Keywords:  Health Care and Public Health

Mesh：

Year:  2003        PMID： 12874159      PMCID： PMC164977     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  15 in total

1.  Opportunity costs and uncertainty in the economic evaluation of health care interventions.

Authors:  P Sendi; A Gafni; S Birch
Journal:  Health Econ       Date:  2002-01       Impact factor: 3.046

2.  Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection.

Authors:  P Sendi; A J Palmer; A Gafni; M Battegay
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures?

Authors:  Amiram Gafni; Stephen Birch
Journal:  CMAJ       Date:  2003-04-01       Impact factor: 8.262

4.  Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty.

Authors:  Pedram Sendi; Maiwenn J Al
Journal:  Soc Sci Med       Date:  2003-09       Impact factor: 4.634

5.  The cost effectiveness of combination antiretroviral therapy for HIV disease.

Authors:  K A Freedberg; E Losina; M C Weinstein; A D Paltiel; C J Cohen; G R Seage; D E Craven; H Zhang; A D Kimmel; S J Goldie
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

6.  Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy.

Authors:  S A Bozzette; G Joyce; D F McCaffrey; A A Leibowitz; S C Morton; S H Berry; A Rastegar; D Timberlake; M F Shapiro; D P Goldman
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

7.  Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study.

Authors:  P P Sendi; H C Bucher; T Harr; B A Craig; M Schwietert; D Pfluger; A Gafni; M Battegay
Journal:  AIDS       Date:  1999-06-18       Impact factor: 4.177

8.  Analysis of costs and cost-effectiveness in multinational trials.

Authors:  M A Koopmanschap; K C Touw; F F Rutten
Journal:  Health Policy       Date:  2001-11       Impact factor: 2.980

9.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

Authors:  S Staszewski; J Morales-Ramirez; K T Tashima; A Rachlis; D Skiest; J Stanford; R Stryker; P Johnson; D F Labriola; D Farina; D J Manion; N M Ruiz
Journal:  N Engl J Med       Date:  1999-12-16       Impact factor: 91.245

10.  The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.

Authors:  Hartmut B Krentz; M Christopher Auld; M John Gill
Journal:  CMAJ       Date:  2003-07-22       Impact factor: 8.262
View more
  1 in total

1.  The increasingly complex fourth hurdle for pharmaceuticals.

Authors:  Joshua Cohen; Elly Stolk; Maartje Niezen
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.